好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical and Magnetic Resonance Imaging Correlates of Challenging Gait Condition in Multiple Sclerosis
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-011

To identify clinical and MRI factors that may influence dynamic balance and the ability to change walking speed during challenging gait condition in multiple sclerosis (MS) patients and in the main clinical MS-phenotypes (RRMS and PMS).

Gait dysfunction and balance impairments are common symptoms in MS patients. Gait function relies on a network of several subcortical and cortical structures, usually affected by MS. Structural damage or functional abnormalities of this network may result in worse challenging gait condition performance.

In this cross-sectional study, 58 MS patients and 30 healthy controls (HC) were retrospectively analyzed. In all subjects, the timed up and go test was performed at comfortable (TUG) and maximum speed; the time difference (TUG-diff) was also calculated. Clinical data related to disability, aerobic capacity, upper limb function, walking capacity and cognitive performance, as well as structural and functional MRI data related to the thalamus, globus pallidus, putamen, caudate nucleus, primary motor cortex (M1), supplementary motor area (SMA), prefrontal (PFC) and premotor cortex (PMC) were obtained.

Compared to HC, MS had worse zTUG/zTUG-diff performance, reduced M1 and SMA cortical thickness (CT); and decreased resting state functional connectivity (RSFC) between the PFC and subcortical nuclei (all-p<0.01). RRMS had a preserved M1 and SMA CT (p>0.12) and a decreased RSFC only between PFC and the caudate nucleus (p=0.03). In MS patients, several motor factors were associated with zTUG/TUGdiff, while zTUGdiff was also correlated with cognitive performance (all-p<0.01). In RRMS, worse zTUG was associated with lower M1 CT (R=0.42), lower SMA CT (R=0.38), and increased RSFC between PFC and the caudate nucleus (R=-0.33; all-p<0.02).

MS patients present impairments in challenging gait condition performance, which are influenced by several motor and cognitive factors. Both structural and functional mechanisms of compensation seem to be present in initial phases of the disease.

Authors/Disclosures
Maria A. Rocca (Neuroimaging Research Unit)
PRESENTER
Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Matteo Albergoni, PT (Ospedale San Raffaele SRL (VAT: IT 07636600962)) Dr. Albergoni has nothing to disclose.
Elena Marabese No disclosure on file
Alessandro Meani Alessandro Meani has nothing to disclose.
Elisabetta Pagani Elisabetta Pagani has nothing to disclose.
Paola Valsasina Paola Valsasina has nothing to disclose.
Paolo Preziosa (Ospedale San Raffaele) Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.